Cardica Changes Company Name to Dextera Surgical (DXTR)
June 20, 2016

Cardica, Inc. (Nasdaq:CRDC), manufacturer of the smallest-profile and most maneuverable articulating surgical stapling platform on the market for minimally invasive surgery, today announced that the company has changed its name to Dextera Surgical Inc. The company’s Nasdaq ticker symbol also will be changing, with its common stock to begin trading under the new ticker symbol “DXTR,” effective Wednesday, June 22.
The new name reflects an evolution for the device company. Dextera’s MicroCutter surgical stapling technology portfolio enables the advancement of minimally invasive and robotic-assisted surgery across a wide variety of clinical applications, broadening the company’s focus beyond its anastomotic product lines originally introduced for use in cardiac surgery.

“Today, we are helping to advance minimally invasive surgery around the world, with products that are helping surgeons operate more effectively in tight spaces through smaller incisions,” said Julian Nikolchev, president and CEO of Dextera. “Our newest technology is making an impact for patients in lung surgery, pediatric procedures and beyond, and the strategic focus of our business has expanded much further than the cardiac products for which our company was originally named. With a new management team and a clear vision forward, we’ve evolved as a company, and we think it’s time our name did too.”

“We love the name Dextera,” Nikolchev continued. “It’s inspired by the word ‘dexterity,’ which emphasizes skill, expertise, agility and finesse. These are qualities we see in our employees, our products and the surgeons who are advancing minimally invasive surgery through the use of smaller, more maneuverable stapling technology.”

It will take several weeks for all company materials, MicroCutter products and packaging to fully transition to the Dextera Surgical brand. During this time, some materials in some countries may continue to reference the Cardica name and logo.

The company’s automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, will continue to be marketed and sold by Dextera under the Cardica brand name. These products have demonstrated long-term reliable clinical performance and remain the only automated anastomosis devices for CABG surgery on the market today.

More information about Dextera can be found on the company’s new website, www.dexterasurgical.com.

About Dextera Surgical
Dextera Surgical designs and manufactures proprietary stapling devices for minimally invasive surgical procedures. In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted or robotic-assisted surgical procedures annually.

The company’s signature proprietary technology, the MicroCutter 5/80, is the world’s first and only five-millimeter surgical stapler that articulates to 80 degrees in each direction. As the smallest-profile articulating stapler available today, the MicroCutter 5/80 may reduce the amount of dissection and tissue handling required to position the stapler in confined spaces, enabling access to difficult-to-reach anatomy. The cartridge-based device’s small size and wide articulation range is designed to enhance the surgeon’s access and visualization at the surgical site, and to mitigate limitations on the advancement of minimally invasive surgical approaches created by larger stapling devices.

MicroCutter Indication Information
The MicroCutter 5/80 is manufactured and cleared for use in the United States for transection and resection in multiple open or minimally invasive urologic, thoracic and pediatric surgical procedures, as well as application for transection, resection and/or creation of anastomoses in the small and large intestine, and the transection of the appendix. The MicroCutter 5/80 White Cartridge staple has application in vascular tissue.

Forward-Looking Statements
The statements in this press release regarding Dextera’s beliefs as to the benefits expected to be obtained from the use of the MicroCutter 5/80, are "forward-looking statements." There are a number of important factors that could cause results to differ materially from those indicated by these forward-looking statements, including: that Dextera may not be successful in its efforts to complete the development of its combination device (designed to use two different size cartridges) or achieve optimization of Dextera’s supply chain for its combination device; that Dextera may not receive regulatory clearance for indications not currently cleared; as well as other risks detailed from time to time in the company's reports filed with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, under the caption “Risk Factors.” Dextera expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Dextera’s reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.


Contact:

Investors:
Bob Newell
Vice President, Finance and Chief Financial Officer
(650) 331-7133
investors@cardica.com

nice bullish close. the day was basically flat and the last 10 minutes price went to the high of the day.

one buy 33,188 shares @ 3.73,...

lets see what good news we receive form the c/c to'morw.

maybe the ISRG is going to pump another $2m into CRDC ior,...a deal is going to manifest and we have royalties coming in,..or something better ?

Cardica to Announce Fiscal 2016 Third Quarter Financial Results on Thursday, May 5, 2016

REDWOOD CITY, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Cardica, Inc. (Nasdaq:CRDC) today announced that it will release financial results for its fiscal third quarter ended March 31, 2016, on Thursday, May 5, 2016, after the markets close. Cardica’s management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company’s business.

Conference Call Details
To access the live conference call on May 5, 2016, at 4:30 p.m. Eastern Time via phone, please dial 877-797-0722 from the United States and Canada or 615-247-0191 internationally. The conference ID is 97363213. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately four hours after the call through May 12, 2016, and may be accessed by dialing 855-859-2056 from the United States and Canada or 404-537-3406 internationally. The replay passcode is 97363213.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company’s website at www.cardica.com. Please connect to the website at least 15 minutes prior to the presentation to allow for any necessary software downloads.

The webcast is also being distributed through the Thomson StreetEvents Network. Institutional investors can access the call via Thomson StreetEvents at www.streetevents.com, a password-protected event management site.

About Cardica
Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and minimally invasive surgical procedures. Cardica's technology portfolio is intended to reduce operating time and facilitate minimally invasive and robot-assisted surgeries. Cardica’s MicroCutter XCHANGE® 30, that includes a cartridge-based articulating surgical stapling device with a five-millimeter shaft diameter and staples, is manufactured and cleared for use in the United States for transection and resection in multiple open or minimally invasive urologic, thoracic and pediatric surgical procedures, as well as application for transection, resection and/or creation of anastomoses in the small and large intestine and the transection of the appendix. The MicroCutter XCHANGE 30 White Cartridge staple has application in vascular tissue. In addition, Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and has shipped over 56,500 units throughout the world.

Contact:

Bob Newell
Vice President, Finance and Chief Financial Officer
(650) 331-7133
investors@cardica.com

Cardica Announces First Procedures in U.S. Using MicroCutter XCHANGE® 30 Following Expanded FDA Indication
April 18, 2016

Smallest Articulating Surgical Stapler Utilized During Robotically Assisted Thoracic Surgeries


Cardica, Inc. (Nasdaq:CRDC) today announced that the first U.S. cases using the company’s MicroCutter XCHANGE® 30 surgical stapler in thoracic surgery procedures have been performed by Robert J. Cerfolio, M.D., at the University of Alabama at Birmingham's Comprehensive Cancer Center. MicroCutter XCHANGE® 30, the world’s smallest-profile articulating stapler available, was successfully used during a number of recent robotically assisted cancer surgeries to remove portions of the lung, including both lobectomy and segmentectomy procedures.

Surgical staplers are routinely used in the U.S. in more than one million minimally invasive laparoscopic, video assisted or robotically assisted surgical procedures annually. The procedures performed by Dr. Cerfolio represent the first time the MicroCutter XCHANGE 30 has been used in thoracic surgeries under the expanded indication the company received from the U.S. Food and Drug Administration (FDA). In January, the FDA provided 510(k) clearance for use of the device with a white cartridge for the transection and resection in open or minimally invasive urologic, thoracic, and pediatric surgical procedures. Previously, indications for use of the MicroCutter XCHANGE 30 included surgical procedures in the small and large intestine and the appendix.

“The MicroCutter XCHANGE 30 represents an important advancement in stapling that has the potential to change the landscape of thoracic surgery as we work to make it less invasive to our patients,” said Dr. Cerfolio. “With its small size and increased articulation, the MicroCutter XCHANGE 30’s unique design enables surgeons to maneuver around vessels more easily, potentially reducing dissection while achieving good hemostasis, all through a tiny five-millimeter port.”

“We are proud to support leading thoracic surgeons like Dr. Cerfolio as they constantly strive towards less-invasive approaches and better patient outcomes in thoracic surgery,” said Julian Nikolchev, president and CEO of Cardica. “We are pleased that, with this expanded FDA indication, the MicroCutter XCHANGE 30 is providing new options for surgeons, and enabling the continued progression toward these less-invasive approaches.”

About MicroCutter XCHANGE 30
The MicroCutter XCHANGE 30, the world’s first and only five-millimeter surgical stapler that articulates to 80 degrees, is a cartridge-based minimally invasive surgical stapling system. The device’s small size and wide articulation range is designed to enhance the surgeon’s access and visualization at the surgical site, and to mitigate limitations on the advancement of minimally invasive surgical approaches created by larger stapling devices. As the smallest-profile articulating stapler available today, the MicroCutter XCHANGE 30 is designed to reduce the amount of dissection and tissue handling required to position the stapler in confined spaces, enabling access to difficult to reach anatomy. In January 2016 the FDA provided 510(k) clearance for the use of the device for transection and resection in multiple open or minimally invasive urologic, thoracic, and pediatric surgical procedures, as well as applications for transections, resection, and/or creation of anastomoses in the small and large intestine, and the transection of the appendix.

About Cardica
Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and minimally invasive surgical procedures. Cardica's technology portfolio is intended to reduce operating time and facilitate minimally invasive and robot-assisted surgeries. Cardica’s MicroCutter XCHANGE® 30, that includes a cartridge-based articulating surgical stapling device with a five-millimeter shaft diameter and staples, is manufactured and cleared for use in the United States for transection and resection in multiple open or minimally invasive urologic, thoracic and pediatric surgical procedures, as well as application for transection, resection and/or creation of anastomoses in the small and large intestine and the transection of the appendix. The MicroCutter XCHANGE 30 White Cartridge staple has application in vascular tissue. In addition, Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and has shipped over 56,500 units throughout the world.

http://phx.corporate-ir.net/phoenix.zhtml?c=195013&p=irol-newsArticle&ID=2157848

CRDC Confidential Agreement,...

something's up ,...ISRG or another interested party ?

ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Cardica, Inc.
File No. 000-51772 - CF#33390

http://www.sec.gov/Archives/edgar/data/1178104/999999999716021983/filename1.pdf

CRDC has been consistently up for the last two weeks. low volume accumulation moving price,...50ma/200ma already accomplished,...MACD ready for a crossover,..MACD Histogram moving into buy territory,...

lookin' reallll good !

CRDC chart looking very excellent here,..technically.

lets hope whats going on behind the scenes is a positive as the chart ,...

CIMA check out this link, Photos of VPC investors at the Barney Visser Show, do you recognise any of those investors? Explains a lot doesn't it, a break away group of lqmt investors trying to destroy lqmt so that VPC can become the worlds BMG manufacture. Or that WAS the plan.
http://apicscolorado.org/gallery.php?id=29&bypassCookie=1

Not only have I been following $CRDC, I've made Great $$$$$ in $CRDC. I initiated my Long position & started accumulating shares of $CRDC on January 7th, after the company amended its license agreement with $ISRG (Reference Attached Link). In addition, Cardica's MicroCutter XCHANGE30 could be a game changer for $CRDC & make the company a possible acquisition target. $CRDC's short-term & long-term insider trading has been very positive. Furthermore, I see more upside potential for $CRDC from its current PPS & will be holding my Long position.

http://www.streetinsider.com/dr/news.php?id=11201207

That's good stuff for those of us who are sitting back accumulating.

I bought just before split when I got word of their device. Sold a few shares, Been holding the rest, possibly buying more.

it's still under the radar of the big bouys of wall street. i've been on this for a solid year plus just collecting shares. my average is .295 with the split $2.95,...

a lot of other savvy investors are in CRDC,...they like myself are just waiting for our new CEO to kick it into gear.

recent insider buying, ISRG infusion of funds,volume picking up...looks good to me.

you a CRDC shareholder or just trading it ?

there might be a little pullback to 3.89-3.75,...daytraders might sart to enter more because volume is picking up. a nice 200+ day with 147+ in buys and 49k in sells,..3 day rule might kick in for some profit taking,...

if CRDC does not collapse like the markets will be then we have another leg up,...

some nice buys today hopefully continuing.

I can't believe no one on here is following this stock. Lol

she keeps going , insane

moving very nicely today,...high of $4.04 so far with some decent buying. at this rate we see 120,000+ in volume,...new leg starting ?

nice close on fairly decent volume. the markets wer weak but CRDC held up. lets see what Monday brings.

CRDC 45k bid at 3.68 $$$$

CRDC is up 42% this week ! very nice move. we need more volume, at least 120,000 for this breakout to hold.

it's already moved past the 200ma which is at $3.10 and the 50ma is moving upwards,..so some strength is showing.

if the major markets fall, which is likely and CRDC price can stay above $3.10 that is a very positive signal.

looks like we hit $4 today and potentially $4.25 as the close,...

price is going to punch through the 200ma,...new leg beginning

3.90 Ah!

Bidders have returned

shorters trying hard

Good trade from 2.70s.. Picking up nicely here

FOLLOW THE LEADERS ..CRDC 3.50

BIDDERS HAVE ARRIVED..

should see some bidders step up..

CRDC Insider buys in Feb 2016 and chart ==>

Purchase 2016-02-23 2016-02-24 20:04:12 CARDICA INC CRDC Nikolchev Julian CEO 1,146 $2.60 $2,979.60 7,610 view

Purchase 2016-02-22 2016-02-24 20:04:12 CARDICA INC CRDC Nikolchev Julian CEO 2,696 $2.60 $7,009.60 6,464 view

Purchase 2016-02-24 2016-02-24 20:03:51 CARDICA INC CRDC Bates Michael A. director 26,600 $2.99 $79,534.00 54,600 view

Purchase 2016-02-23 2016-02-24 20:03:51 CARDICA INC CRDC Bates Michael A. director 5,000 $2.63 $13,150.00 28,000 view

Purchase 2016-02-22 2016-02-24 20:03:51 CARDICA INC CRDC Bates Michael A. director 2,000 $2.62 $5,240.00 23,000 view

Purchase 2016-02-19 2016-02-19 19:40:10 CARDICA INC CRDC Bates Michael A. director 1,000 $2.53 $2,530.00 21,000

technical breakout is at $3.70,...then we go !

of course, this market is sucking so who knows what will actually occur.

but the insider buying is very positive since there has been no insider for several months/years.

Cardica Inc (CRDC) Files Form 4 Insider Buying : Julian Nikolchev Buys 3,842 Shares

Cardica Inc (CRDC): Julian Nikolchev , CEO of Cardica Inc purchased 3,842 shares on Feb 22, 2016. The Insider buying transaction was disclosed on Feb 24, 2016 to the Securities and Exchange Commission in a Form-4 filing. The shares were purchased at $2.60 per share for a total value of $9,989.20.

According to SEC Form 4 filings, on Feb 24, 2016, Michael A. Bates (director) purchased 33,600 shares at $2.75 per share price.On Feb 12, 2016, Robert Y Iv Newell (CFO) purchased 40,000 shares at $0.26 per share price.Also, On Feb 11, 2016, Julian Nikolchev (CEO) purchased 37,680 shares at $0.27 per share price.On Feb 10, 2016, Gregory P. Watson (V.P., Operations) purchased 75,000 shares at $0.25 per share price

flag breaking 200d test coming

CRDC,...Cardica reverse splits stock 1:10 effective today
Feb 17 2016, 10:16 ET

Thinly traded micro cap Cardica (CRDC +773.8%) reverse splits its common stock 1:10 in order to regain Nasdaq listing requirements. Post-split shares are trading today.

http://seekingalpha.com/news/3113776-cardica-reverse-splits-stock-1-10-effective-today?uprof=54#email_link

R/S takes place today 2.65 pre

It looks like the 1:10 reverse split is in process and could take effect as soon as tomorrow morning. This should be a very interesting year for the company.

i think CRDC shareprice will possibly take a dip along with the entire (bear) market we are in,..it just happens that way. that's o.k. by me... more shares to collect.

the main aspect to me this company is in a sector that has the big boys are in watch mode and if they like what they see its mergers and/or buyouts.

ISRG, and this was covered in the c/c, if the device performs to ISRG standards and/or exceeds them there is a royalty licensing fee that goes to CRDC,..more cash hence making CRDC shareprice via a buyout more valuable. and that is what we shareholders know. what else is being worked out that we are not aware of.

from the transscript;

Once Intuitive completes the evaluation, they will have the option to initiate a joint development program for an 8 millimeter surgical stapling cartridge for use with robotic applications.

If Intuitive elects to move forward with the development, we would receive further funding as well as unit based royalty on commercial sales.


the way i figure it if there is a buyout CRDC shareholders could see a nice pop,...i think, and this is purely speculation, $8- $15 a share where it stands now. if the Gen4 really comes out strong and becomes a game changer ,..$12- $25. i'm hoping Gen$ is such a strong surgical advantage that there is a bidding war.

from the transcript;

We expect to complete the first evaluation cases with the Generation 4 device in the third quarter of calendar 2016 with a selected launch target for the fourth quarter of calendar 2016. By the end of the year, we tend to have an improve supply chain, using the most appropriate technologies. Finally, we expect to announced our product pipeline moving forward into 2017.

and here's another diamond that was mentioned in the transcript;

In December, we were pleased to announce that we signed a national innovative technology contract with Novation, the country’s leading healthcare services company with more than 5,200 health system members, including such prestigious names as VHA, UHC, Children’s Hospital Association and Provista. This three year contract with the MicroCutter XCHANGE 30 complements our commercial efforts by enabling Novation members and affiliates to quickly navigate the purchasing process with a designated contracting pathway within their hospitals and health systems.

winner , winner , chicken dinner.

CRDC Transcript;

http://seekingalpha.com/article/3867326-cardicas-crdc-ceo-julian-nikolchev-q2-2016-results-earnings-call-transcript?part=single

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

sorry to hear about your losses. most pinks, at least 99% are total bs companies with bs ceo's.

that is why i have stayed away from pinks. all they do is scam. i've been mainly playing options,...a much better opportunity with r.o.i. i mainly play the indices and mainly SPY. doing quite well with it.

I only had a chance to skim over the transcripts, I will be looking over them in detail in the morning. I'm speculating but I believe we will see a nice dip (buying opportunity) prior to the reverse split. I wish I had more to put into this but I recently got scammed by a company on the Pinks :(

I started my account a little over a year ago with $400 and got it to $21,500 and lost almost everything. Time to start all over...

cool ! good fortune to you.

i've been collecting all along the way.

yep, CRDC has the potential to be a game-changer in this sector.

ISRG didn't place $2M in for the hell of it.

if we know what we know via pr's then what might really be talked about behind closed doors for the BoD ears only. not pumping at all,.don't need to.

but the big boy players are J&J, Covidien, ISRG, GE,...to name a few.

CRDC's new CEO (Julian) knows what he is doing,..he's done this type of activity before so we shareholders are in great hands.

i kow you usually do your d/d,..but IF you haven't heard the most recent transcript take a listen.

I'm going to buy in this week. I haven't said this about many stocks, but I believe a reverse split will be a good thing for Cardica. I'm sure there are institutional investors waiting for them to regain compliance with a share price above $1.00.

Saw it. Thanks. Flipped it three times. Made money twice. I can live with that

FYI,...CRDC c/c transcript ==>

http://seekingalpha.com/article/3867326-cardicas-crdc-ceo-julian-nikolchev-q2-2016-results-earnings-call-transcript?auth_param=f4h1u:1bb7par:367a4df698a4bf4a3379a22375451b7c&uprof=54

earnings transcript

And where did you read this, may I ask?

no but i can read....Finally, the Board has approved a reverse stock split at the ratio of one for 10. We intend to affect this split during February.

it's obvious that you are not CRDC shareholder making such an uninformed and ignorant statement,...

you undoubtedly didn't listen to the most recent c/c,...

you have no clue dude.

good luck on your playing it,...wink, wink

that was a given..they always run POS stocks before they announce a split

$CRDC Daily & Weekly Chart

R/S will be 10 for 1 in Feb

If CRDC does a R/S, hope they give it some time. Month or two would be all right. I'm just in this to flip it a few times. Twice so far with decent returns. Will go at it again Wed.

not that it means or interprets into anything other than what is stated,..

but this is a little piece of info i found interesting,..granted i'm attempting to connect some dots that might be non-existent.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

so if J&J is a potential buyer of ISRG and IRSRG has placed $2MM into CRDC for further development of their Xchange surgical cutter that becomes a very interesting development.

then there is also other big boys that are seeking out investments in this sector specifically,..GOOG being one of those and also GE,...

so,...CRDC will have a game changer product with their 5m cutter,...it has and will get continued attention as developments are positive.

like i mentioned there might not be any factual and/or real dots to connect,..but it's fun speculating ;^)

the story ==>

~~~~~~~~~~~~~~~~~~~~~~~~~~~~

3 Health Care Stocks to Own in a Dangerous Market

2. Intuitive Surgical Inc. (ISRG - Get Report)

With robotic-assisted surgery gaining ground, medical appliances and equipment firm Intuitive Surgical has immense growth potential.

Intuitive manufactures da Vinci Surgical Systems and related instruments and accessories which are used in robotic-assisted surgery.

ISRG could also be a potential takeover candidate for Johnson & Johnson, which is on the prowl for acquisitions in the surgical robot space.

While the company cooled off slightly with its three-year average revenue growth down below 7% and net income dropping below the industry average, it is showing promising signs of growth in 2015. Annual revenues for 2015 grew to $2.38 billion, up nearly 12% and net income surged over 40% to $588 million.

Analysts expect the company to grow earnings by over 14% annually in the next five years, pacing ahead at a rate much faster than the 9.03% recorded in the previous half a decade.

With over $3.3 billion in cash (nearly 20% of share value), zero debt and profit margins of nearly 25%, Intuitive Surgical checks the boxes of being a performer suitable for long-term investors. The fact that the ISRG stock trades at a 5-year expected PEG ratio of 1.81 vis-a-vis larger medical device firms like Medtronic at 2.47 and Stryker Corp at 1.86 makes it even more attractive.

depends how one defines the 'foreseeable future'. 1 month, 3 months, 6months ?

i think CRDC has to perform a R/S,...i'm thinking 10 to 1 making the shareprice approximately $3,..OR a 20 to 1 making it approximately $6.

i think we see it in 3 months or less. granted thats a WAG.

what is your time frame guess ?